Key result
Moderate reductions in eGFR (50-59 ml/min/1.73 m2) were associated with an increased adjusted risk for death only among patients younger than 65 years, indicating a weaker association in the elderly.
Why the study?
Does the prognostic significance of eGFR for mortality differ by age group in patients with chronic kidney disease?
Cohort (n=2,583,911)
Yes
Does the prognostic significance of eGFR for mortality differ by age group in patients with chronic kidney disease?
Mortality risk stratification in elderly patients should use different eGFR cut points than younger patients, as moderate eGFR reductions (50-59 ml/min/1.73 m2) do not increase mortality risk in those over 65.
No takes yet. Share an insight, caveat, or question.
eGFR 50-59 ml/min/1.73 m² should not yet alter mortality risk assessment in patients >65; leaves open age-specific prognostic thresholds in CKD.
O’Hare et al. (2006) conducted a cohort in Chronic Kidney Disease (n=2,583,911). Estimated GFR (eGFR) levels vs. Different age groups was evaluated on Mortality. Moderate reductions in eGFR (50-59 ml/min/1.73 m2) were associated with an increased adjusted risk for death only among patients younger than 65 years, indicating a weaker association in the elderly.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: